BRAF and Miyoshi myopathy: Although the front-line anti-PD-1-based immunotherapy remains the preferred approach for advanced CM without BRAF mutations, incorporating VEGF-targeting therapy with immunotherapy could potentially improve the clinical response in patients with MM.